Navigation Links
Diagnostic Marketing Association Names Cepheid 2011 Marketer of the Year
Date:5/1/2012

INDIANAPOLIS, May 1, 2012 /PRNewswire/ -- The Diagnostic Marketing Association (DxMA), serving marketing, regulatory and medical affairs professionals in the diagnostic and device market segments, today presented its 2011 Marketer of the Year Award to Cepheid (Nasdaq: CPHD), a leading molecular diagnostics company. Presented at the annual DxMA Global Marketing Summit, the award recognizes innovation by marketers seeking to highlight their company and products at the leading edge of the diagnostic industry.

Cepheid was selected for its "Art Meets Innovation" campaign.  To unveil its redesigned GeneXpert® Systems at the 2011 American Association of Clinical Chemistry and Clinical Lab Expo, Cepheid partnered with Paul Jr. Designs, a world-renowned builder of custom motorcycles, to build a custom bike themed on its new GeneXpert Systems and molecular diagnostic testing. The live unveiling event was filmed for the popular Discovery Channel show American Chopper. The epic bike had to be "as cutting edge and innovative, yet as elegant as our technology," said Cepheid CEO John Bishop. An entire marketing campaign, including a road show with the bike, was developed around the 'Art Meets Innovation' theme.

"The Marketer of the Year Award is the highest accolade DxMA offers for diagnostic companies," said Robter Speziale, President DxMA. "It recognizes outstanding work that raises the bar in diagnostics marketing. In a crowded field, Cepheid stood out with its 'Art Meets Innovation' marketing campaign, by demonstrating the strongest commitment to marketing innovation, boldness and execution that symbolizes both Cepheid and its GeneXpert on-demand molecular testing technology."

To learn more about the Cepheid Bike and GeneXpert campaign, visit http://www.cepheid.com/cepheid-bike/.

About DxMA (Diagnostic Marketing Association)

The DxMA builds diagnostic industry leadership by providing knowledge and opportunities for professional development and the exchange of ideas. We serve marketing, regulatory compliance and medical affairs professionals who have devoted their careers to the diagnostics and device market segments. Members benefit from continued education and insight, networking with marketers from leading diagnostic companies and service providers, and the AACC seminar and DxMA Global Marketing Summit. For more information on the DxMA, visit www.dxma.org.

About Cepheid

Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer.

Contact
Debra Harrsch
Brandwidth Solutions LLC
215 997-8575
Dharrsch@brandwidthsolutions.com


'/>"/>
SOURCE The Diagnostic Marketing Association
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Inverness Medical Innovations Features Innovative TB Diagnostic - Clearview(R) TB ELISA at AIDS 2008
2. Biotest Diagnostics Receives FDA Clearance for Full Line of Traditional Blood Bank Reagents
3. VentriPoint Diagnostics Files Management Discussion and Analysis, Unaudited Financial Results for 2Q 2008
4. Exosome Diagnostics Announces Additions to Management Team
5. Pathwork Diagnostics Closes $20M Financing
6. Boveran Diagnostics, Inc. Announces Planned Acquisition of New York-Based Pathology Lab: Sophora Diagnostic Lab, Inc.
7. Exosome Diagnostics Appoints Johan Skog, Ph.D., as Director of Genetics Research
8. Inverness Medical Innovations to Attend the Goldman Sachs Diagnostics Conference on September 18, 2008
9. Enigma Diagnostics Announces an Award of GBP 1.8 Million From UK Government
10. MediCult Acquires US-Based MidAtlantic Diagnostics to Further Strengthen ART Presence
11. Cepheid Receives FDA Clearance for First Rapid On-Demand Molecular Diagnostic Test for MRSA and S. aureus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 2016  Vermillion, Inc. (NASDAQ: VRML ), a ... the formation of the Steering Committee for its Pelvic ... --> Pelvic masses can present physicians and healthcare ... pregnancy is ruled out, pelvic masses may include cancers ... benign ovarian tumors and gastrointestinal and urinary tract masses. ...
(Date:2/11/2016)... BioPharma Selling Solutions (Spectra) is a new Contract ... experience, expertise, operational delivery and customer focus to ... in concert with industry leading commercial experts, the ... needs of its clients by providing value-based creative ... non-personal promotion. --> ...
(Date:2/11/2016)... Calif. , Feb. 11, 2016  Dovetail Genomics™ ... to its beta program for a planned metagenomic genome ... present the company,s metagenomic genome assembly method in a ... in Genome Biology & Technology conference in ... of these highly complex datasets is difficult. Using its ...
(Date:2/11/2016)... ... February 11, 2016 , ... Reichert Technologies, which has ... to pursue the highest level of accuracy and quality with the addition of ... the AR5 Refractometer. Accurate, reliable and tough enough for the most demanding ...
Breaking Biology Technology:
(Date:2/3/2016)... -- --> --> ... Identification System Market by Component (Hardware and Software), Search ... Government, Healthcare, and Transportation) and Geography - Global Forecast ... to be worth USD 8.49 Billion by 2020 at ... The transformation and technology evolution from the manual process ...
(Date:2/2/2016)... , Feb. 2, 2016 Checkpoint Inhibitors ... Rising Market Are you interested in the ... revenues for checkpoint inhibitors. Visiongain,s report gives those ... product and national level. Avoid falling behind ... progress, opportunities and revenues those emerging cancer therapies ...
(Date:2/1/2016)... , Feb. 1, 2016  Today, the first day ... announced plans to develop a first of its kind ... of IBM Watson. In the first application of ... (NYSE: IBM ), and Welltok will create a ... assessments with cognitive analytics, delivered on Welltok,s health optimization ...
Breaking Biology News(10 mins):